title: [Combination of lapatinib with chlorogenic acid inhibits breast cancer metastasis by suppressing macrophage M2 polarization].
abstract: To determine the effect of the combination of lapatinib with chlorogenic acid on metastasis of breast cancer in mouse model.
  
  
  
  The classical macrophage M2 polarization model induced by interlukin13in vitro was adopted in the study. Flow cytometric analysis was performed to detect the expression of M2 marker CD206. The transcription of M2-associated genes was measured by RT-PCR. HE staining was used to analyze the metastatic nodes of breast cancer in lungs of MMTV-PyVT mice. Immunostaining analysis was used to detect the expression of related proteins in breast cancer.
  
  
  
  The combination of lapatinib and chlorogenic acid inhibited the expression of CD206 induced by IL-13[(42.17%±2.59%) vs (61.15%±7.58%), P<0.05]. The combination more markedly suppressed expression of M2-associated gene Ym1 than lapatinib alone[(0.9±0.1) vs (1.8±0.0), P<0.05]. The combination of lapatinib and chlorogenic acid significantly reduced metastatic nodes in lung[P<0.05], and also significantly decreased the percentage of CD206(+) cells in breast cancer compared to controls[(6.08%±2.60%) vs(29.04%±5.86%), P<0.05].
  
  
  
  The combination of lapatinib and chlorogenic acid can effectively inhibit macrophage M2 polarization and metastasis of breast cancer.
authors.affiliation: College of Pharmaceutical Sciences, Zhejiang University, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Hangzhou 310058, China.
authors.forename: Jie-qiong
authors.initials: JQ
authors.lastname: Zhang
authors.affiliation: College of Pharmaceutical Sciences, Zhejiang University, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Hangzhou 310058, China.
authors.forename: Zhang-ting
authors.initials: ZT
authors.lastname: Yao
authors.affiliation: College of Pharmaceutical Sciences, Zhejiang University, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Hangzhou 310058, China.
authors.forename: Gui-kai
authors.initials: GK
authors.lastname: Liang
authors.affiliation: College of Pharmaceutical Sciences, Zhejiang University, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Hangzhou 310058, China.
authors.forename: Xi
authors.initials: X
authors.lastname: Chen
authors.affiliation: College of Pharmaceutical Sciences, Zhejiang University, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Hangzhou 310058, China.
authors.forename: Hong-hai
authors.initials: HH
authors.lastname: Wu
authors.affiliation: Department of Neurology, the Second Affiliated Hospital Wenzhou Medical University, Wenzhou 325027, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Jin
authors.affiliation: College of Pharmaceutical Sciences, Zhejiang University, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Hangzhou 310058, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Ding
mesh_terms: D000818:Animals; D002726:Chlorogenic Acid / Q000494:pharmacology*; D005260:Female; D000077341:Lapatinib; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008264:Macrophages / Q000187:drug effects*; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D051379:Mice; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D011799:Quinazolines / Q000494:pharmacology*
chemical_list: D011799:Quinazolines; D000077341:Lapatinib; D002726:Chlorogenic Acid